Conduit Pharmaceuticals Operating Income

As of the most recent data (June 2026), CDT shows a operating income of $600M. That compares with $220M in the prior-year period — up 169.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CDT's operating income is now $600M (was $220M) — a 169.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Conduit Pharmaceuticals is outperforming or lagging.

Tracking CDT's operating income over time shows whether Conduit Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $600M That compares with $220M in the prior-year period — up 169.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Conduit Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $600M) with ownership activity and broader fundamentals.